Laurent Fischer, M.D. is Adverum’s president and chief executive officer and serves as a director. Dr. Fischer has more than 20 years of drug development and commercialization experience in the biopharmaceutical industry. Before joining Adverum, Dr. Fischer was senior vice president and head of the Liver Therapeutic Area at Allergan, PLC. Previously, he served as chairman and chief executive officer of Tobira Therapeutics until its acquisition by Allergan in November 2016. Previously, he served as chairman and chief executive officer of Jennerex, Inc. until its acquisition by SillaJen Biotherapeutics, Inc. Prior to Jennerex, he was co-founder, president and chief executive officer of Ocera Therapeutics and president and chief executive officer of Auxeris Therapeutics, Inc. Over the span of his career, Dr. Fischer has held roles of increasing responsibility at several companies, including, RXCentric, Inc. (now part of Allscripts Healthcare Solutions, Inc.), MedVantx Inc., Dupont Pharmaceuticals, Dupont-Merck, and F. Hoffmann-La Roche.
Dr. Fischer received his undergraduate degree from the University of Geneva and his medical degree from the Geneva Medical School, Switzerland.
Dr. Fischer currently serves as chairman of the board of CTI Biopharma, as director at Mirum Pharmaceuticals, Inc. and Lycia Therapeutics, and as senior advisor on the Life Sciences Team at Frazier Healthcare Partners.
What is Laurent Fischer's net worth?
The estimated net worth of Laurent Fischer is at least $365.80 thousand as of December 5th, 2025. Dr. Fischer owns 83,899 shares of Adverum Biotechnologies stock worth more than $365,800 as of December 16th. This net worth approximation does not reflect any other investments that Dr. Fischer may own. Additionally, Dr. Fischer receives a salary of $1,020,000.00 as CEO at Adverum Biotechnologies. Learn More about Laurent Fischer's net worth.
How old is Laurent Fischer?
What is Laurent Fischer's salary?
How do I contact Laurent Fischer?
Has Laurent Fischer been buying or selling shares of Adverum Biotechnologies?
In the last ninety days, Laurent Fischer has bought $553,916.74 in Adverum Biotechnologies stock. Most recently, on Monday, December 8th, Laurent Fischer bought 117,614 shares of Adverum Biotechnologies stock. The stock was acquired at an average cost of $4.31 per share, with a total value of $506,916.34. Following the completion of the transaction, the chief executive officer now directly owns 201,513 shares of the company's stock, valued at $868,521.03. Learn More on Laurent Fischer's trading history.
Who are Adverum Biotechnologies' active insiders?
Are insiders buying or selling shares of Adverum Biotechnologies?
During the last year, Adverum Biotechnologies insiders bought shares 9 times. They purchased a total of 376,822 shares worth more than $1,627,956.75. During the last year, insiders at the biotechnology company sold shares 7 times. They sold a total of 1,112,456 shares worth more than $4,631,759.85. The most recent insider tranaction occured on December, 8th when CEO Laurent Fischer bought 117,614 shares worth more than $506,916.34. Insiders at Adverum Biotechnologies own 6.0% of the company.
Learn More about insider trades at Adverum Biotechnologies. Information on this page was last updated on 12/8/2025.
